Karyn Marie Dyehouse, MD
Fax: (864) 888-8486
About us
Karyn M. Dyehouse, MD is a physician specializing in medical oncology and hematology at the Prisma Health Cancer Institute. She provides general hematology and medical oncology with emphasis on solid tumors such as breast colon and lung cancer. Prior to her work at the Prisma Health Cancer Institute, she served as the Chief Medical Officer at Oncology Hematology Care, in Cincinnati, Ohio.
Dr. Dyehouse earned her medical degree from the University of Cincinnati College of Medicine. She completed her Internal Medicine and Hematology/Oncology Fellowship at University Hospital in Cincinnati, Ohio. She is board certified in both Hematology and Medical Oncology. She is a member of the American Society of Clinical Oncology, the American Society of Hematology, and the American Medical Association. She is also a member of the Alpha Omega Alpha National Honor Society and a former Peace Corp Volunteer.
| Tags | breast cancer immunotherapy, adamantinoma, adjuvant chemotherapy, adult stem cell collection for transplant, adverse effects to anticoagulants, alveolar soft part sarcoma, amyloidosis, anaplastic cancer of thyroid, anemia, anemia of chronic disease, anemia of pregnancy, antithrombin deficiency, aplastic anemia, b12 deficiency anemia, biological targeted therapy, bladder cancer genomics, bleeding disorder, blood cancer, blood disorders, bone marrow disorders, bone sarcoma, brain cancer genomics, breast cancer genetics, cancer, cancer chemotherapy, cancer during pregnancy, cancer genomics, cancer pain, cancer rehabilitation, cancer survivor, cancer related fatigue, cardio oncology, castleman's disease, cervical cancer genomics, cervical teratoma, chemoradiation, colon cancer genomics, cooley anemia, cowden syndrome, cryoglobulinemia, diamond blackfan anemia, diffuse intrinsic pontine glioma (dipg), early detection of cancer, purpura, radionuclide therapy, rectal cancer genomics, reduced intensity conditioning regimens, renal cancer genomics, retroperitoneal mass, rh incompatibility, sacrococcygeal teratoma, sarcoma genomics, secondary polycythemia, side effects of cancer treatment, skin cancer genomics, splenomegaly, stomach cancer, stomach cancer genomics, submucosal tumors, sweat gland carcinoma, tectal glioma, thalassemia, thrombocytopenia, thrombocytosis, thrombophilia, thyroid cancer genomics, endocrine complications of cancer therapy, endometrial cancer, endometrial cancer genomics, epithelioid hemangioendothelioma, factor v leiden, familial aplastic anemia, fanconi anemia, fibrosarcoma of the head & neck, follicular cancer of thyroid, gallbladder cancer genomics, gastrointestinal (gi) cancer genomics, genitourinary cancer genomics, giant cell tumor of the bone, glucose 6 phosphate dehydrogenase deficiency, head and neck cancer, head and neck cancer genomics, hellp syndrome, hemochromatosis, hemoglobinopathies, hemolytic anemia, hemolytic uremic syndrome, heparin induced thrombocytopenia, hereditary cancer risk, hereditary spherocytosis, histiocytosis, hypogammaglobulinemia, idiopathic thrombocytopenic purpura, cancer immunotherapy, iron deficiency anemia, langerhans cell histiocytosis, leukemia genomics, leukopenia, li fraumeni syndrome, liver cancer genomics |